Immunic Inc stock (US45256V1061): Up 124.8% YTD on clinical progress

Immunic Inc (IMUX) shares have surged 124.8% year-to-date to $12.00 as of May 11, 2026, fueled by pipeline advancements in oral therapies for autoimmune diseases. The clinical-stage biotech reported Q4 earnings on February 26.

Immunic Inc stock has delivered strong gains, rising 124.8% year-to-date to $12.00 as of the May 11, 2026 close on Nasdaq, according to MarketBeat as of 05/12/2026. The biotech also issued 4.5 million shares at $13.00-$15.00 per share recently, supporting its clinical development efforts.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Immunic, Inc.
• Sector/industry: Healthcare / Biotechnology
• Headquarters/country: New York, USA
• Core markets: US, Europe
• Key revenue drivers: Clinical-stage immunology therapies
• Home exchange/listing venue: Nasdaq (IMUX)
• Trading currency: USD

Immunic Inc: core business model

Immunic Inc is a clinical-stage biopharmaceutical company developing oral therapies for chronic inflammatory and autoimmune diseases, according to MarketBeat as of 05/12/2026. Founded in 2008 and headquartered in New York with research in Germany, it employs 70 people and focuses on small-molecule immunology to target immune signaling pathways for safer treatments.

The company's strategy emphasizes oral drugs with improved tolerability over injectables, addressing needs in multiple sclerosis, ulcerative colitis and psoriasis. This positions Immunic Inc for US investors tracking biotech innovation in immunology.

Main revenue and product drivers for Immunic Inc

Immunic Inc's lead candidate, vidofludimus calcium (IMU-838), is a DHODH inhibitor in Phase 2 for relapsing multiple sclerosis, Crohn's disease and ulcerative colitis. IMU-935 targets ROR?t for psoriasis, while IMU-856 is in earlier stages, per company overview on MarketBeat as of 05/12/2026.

Future revenue hinges on clinical milestones and partnerships, with no approved products yet. The firm reported quarterly earnings on February 26, 2026, reflecting ongoing R&D investment typical for clinical biotechs.

Industry trends and competitive position

The immunology sector sees rising demand for oral therapies amid US autoimmune disease prevalence, where multiple sclerosis affects over 1 million Americans. Immunic Inc competes with larger players but differentiates via novel mechanisms, appealing to US investors seeking high-growth biotechs.

Why Immunic Inc matters for US investors

Listed on Nasdaq, Immunic Inc offers US investors exposure to cutting-edge immunology pipelines targeting diseases with strong domestic demand. Its New York base and European R&D enhance appeal amid US biotech funding trends.

Conclusion

Immunic Inc has shown robust stock performance with a 124.8% YTD gain to $12.00, driven by clinical progress and capital raises. Investors monitor upcoming trial data and earnings for pipeline validation. The biotech remains focused on oral immunology therapies amid competitive dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.